// App-Quantinova.ai

1078 : The impact of patient-related factors on the occurrence of febrile neutropenia in breast cancer patients receiving (neo-)adjuvant chemotherapy with 5-fluorouracil, epirubicin, and cyclofosfamide (FEC) x6 or FEC x3 followed by docetaxel (D) x3.

Researchers

Presenter

  • Christof Vulsteke

Principal Investigators

  • Alena Pfeil

  • Ruth Pettengell

  • Anne-Sophie Dieudonne

  • Sigrid Hatse

  • Patrick Neven

  • Diether Lambrechts

  • Hans Wildiers

Medical Centers

  • University Hospital Leuven, Department of General Medical Oncology, Leuven, Belgium

  • University Hospitals Leuven, Department of General Medical Oncology, Leuven, BelgiumSt. Georges University of London, London, United KingdomHospital Gasthuisberg, Leuven, Belgium

  • University of Basel, Institute of Pharmaceutical Medicine, ECPM, Basel, Switzerland

  • Catholic University Leuven, Department of Oncology, Leuven, Belgium

  • Catholic University Leuven, Department of Oncology and Vlaams Instituut voor Biotechnologie (VIB), Vesalius Research Center, Leuven, Belgium

  • Catholic University Leuven, Department of Oncology, Leuven, Belgium

Locations

  • Switzerland

  • Belgium

Companies

  • N/A

Study Components

Therapeutic Area

  • Oncology (ONC)

Disease

  • Breast cancer

  • Neutropenia

  • Solid malignancies

Biomarkers

  • Aspartate aminotransferase

  • Circulating tumor cells

  • Creatinine

Drug/Treatment

  • Adrucil injection

  • Epirubicin

  • Docetaxel

  • FEC x3

Outcome

  • N/A

Study Design

  • N/A

Phase

  • NA

Study Id's

  • N/A

Sponsors

  • N/A

Result

  • N/A

Copyright © 2026. QuantiNova All rights reserved